To include your compound in the COVID-19 Resource Center, submit it here.

FDA worries about Amplichip

A long-simmering debate at FDA over the best way to regulate microarrays has come to a boil with Roche Molecular Diagnostic’s decision to market its Amplichip CYP450DNA microarray without seeking prior approval from the agency. The Amplichip thus may become a test case for the agency’s rules on microarray diagnostics.

When Roche (SWX:ROCZ,

Read the full 524 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE